Press Release – New York, NY – April 24, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in approximately $4.8 million registered direct offering of its common sale and purchase of 571,592 shares of its common stock and warrants to purchase 571,592 shares of its common stock.
The Sichenzia Ross Ference Carmel LLP team was led by partners Marc J. Ross, Thomas Rose, David Manno, Matt Siracusa and associate Soumya Cheedi.
